Efficacy Of Neutriderm KS Cream For Scars, Acne Scars And Stretch Marks

A Clinical Study To Evaluate The Efficacy Of Neutriderm KS Cream For Scars, Acne Scars And Stretch Marks - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2025/10/096695

Enrollment

Registered

2025-10-31

Start date

Unknown

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Test Product: Neutriderm KS Cream: Test Product: Neutriderm KS Cream Dose: Apply 0.5gm twice a day. Route of Administration: Topical, Duration: 90 days Control Intervention1: Not App

Eligibility

Inclusion criteria

Inclusion criteria: 1. Gender: Male and Female aged between18-50. 2. Non-pregnant, non-lactating female 3. Subject has Scar, Acne mark and Stretch marks. 4. Subject willing to give written informed consent 5. Women of child bearing potential must have a negative urine pregnancy test. 6. Free of any systemic and dermatologic disorder, which in the opinion of the investigator, will interface with the study results or increase the risk of AE. 7. Are willing to avoid prolonged exposure of the treatment area to ultraviolet radiation (natural or artificial) for the duration of the study.

Exclusion criteria

Exclusion criteria: 1. Subjects who are pregnant, breast feeding, or planning to become pregnant during the study 2. Have any evidence of systematic cancer, squamous cell carcinoma, basal cell carcinoma in the last 5 years, or any other confounding skin condition. 3. Have open sore or open lesions in the treatment area 4. Have any condition that, in the opinion of the investigator, would confound the safety and efficacy assessments of the product. 5. Have participated in any interventional clinical trial in the previous 30 days. 6. Have a known sensitivity to any of the constituents of the test product including sensitivities to any of the constituents. 7. Have used, are using, or are planning to use immunosuppressive or immunomodulatory medications (i.e., biologics), including corticosteroids. 8. Have a history of alcohol or illegal drug/ substance abuse or suspected alcohol or illegal drug/substance abuse in the past 2 years.

Design outcomes

Primary

Measure	Time frame
1. Change in Skin Elasticity 2. change in height 3. Change in Skin Color 4. Change in skin hydration 5. Change in TEWLTimepoint: At T0, 30days, 60 days and 90 Days	—

Secondary

Measure	Time frame
Not ApplicableTimepoint: Not Applicable	—

Countries

India

Contacts

Public ContactPuneet Mittal

CCFT Laboratories

puneetmittal@mgcts.org08937015757

Outcome results